Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
21. November 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (NASDAQ: DYAI), a global biotechnology company, announced today that it has been awarded a $3 million grant from the Gates...
Dyadic Announces Third Quarter 2024 Financial Results and Strategic Progress Across Key Markets
12. November 2024 16:05 ET
|
Dyadic International, Inc.
Highlights Revenue Milestones and Expands Alternative Protein & Pharmaceutical Partnerships with Dapibus™ & C1 Technology Platforms Alternative Proteins Demonstrated substantial revenue...
Dyadic to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
04. November 2024 16:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient...
Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions
21. Februar 2024 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced...
Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform
18. April 2023 08:30 ET
|
Dyadic International, Inc.
JUPITER, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building...
Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
07. März 2023 08:30 ET
|
Dyadic International, Inc.
Dosing of all patients was completed at the end of February No Serious Adverse Events (SAE’s) have been reported Phase 1 clinical initial safety and antibody response update expected in Q2, 2023 ...
Restaurants are Dealing with a National Egg Shortage and Steep Price Increase. Here’s How Some are Fighting Back
19. Januar 2023 06:00 ET
|
Zero Egg
North Riverside, Illinois, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Nationwide consumers and restaurants alike are having difficulty finding eggs, and when they can find them they’re facing insane prices....
Animal Protection Party of Canada recommends municipalities err on the side of caution when it comes to backyard chickens
13. April 2022 16:24 ET
|
Animal Protection Party of Canada
WINNIPEG, Manitoba, April 13, 2022 (GLOBE NEWSWIRE) -- With more Canadian municipalities exploring the trend of backyard chicken-keeping, the Animal Protection Party urges restraint. “We’re in the...
PositiveID Corporation Completes Milestone in Development of Its Firefly Dx Prototype
13. Januar 2015 08:30 ET
|
PositiveID Corporation
DELRAY BEACH, Fla., Jan. 13, 2015 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCQB:PSID), a developer of biological detection and diagnostics solutions, announced today...
A Clinical Update on the Search for a Universal Flu Vaccine: Presentation in Washington, DC on January 30, 2014 in Conjunction With the American Society for Microbiology (ASM) Biodefense Conference
28. Januar 2014 08:30 ET
|
AIM ImmunoTech Inc.
PHILADELPHIA, Jan. 28, 2014 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that the ASM Biodefense Meeting is scheduled for January 27-29, 2014 at the Washington Marriott...